容量扩张与去甲肾上腺素剂量增加对脓毒性休克患者毛细血管再充盈时间的影响
在69例脓毒性休克患者中,33例接受500 mL生理盐水扩容,36例接受去甲肾上腺素剂量增加,采用视频法标准化指尖压力连续5次测量CRT。CRT最小显著变化为23%。基线CRT≥3 s且扩容后CI增加<15%的液体无反应者(n=13)中,除1例外CRT不变;液体反应者中CRT仅8例下降。去甲肾上腺素后MAP增加<15%者(n=6)除1例外CRT无显著变化。大循环指标与CRT变化存在分离,CRT表现如微循环标志物。
要点
- CRT最小显著变化为23%,变化需大于23%才视为有意义。
- 基线CRT≥3 s且扩容后CI增加<15%的液体无反应者(n=13)中,除1例外CRT保持不变。
- 基线CRT≥3 s的液体反应者(n=13)中仅8例CRT下降,其余不变,CI与CRT反应分离。
- 基线CRT≥3 s且去甲肾上腺素后MAP增加<15%者(n=6)中,除1例外CRT无显著变化。
- 基线CRT延长的去甲肾上腺素反应者(n=11)中4例CRT升高,其余不变,MAP与CRT反应分离。
适用人群与场景
- 69例脓毒性休克患者,其中33例接受500 mL生理盐水扩容,36例为不同患者接受去甲肾上腺素剂量增加。
诊断标准与关键阈值
- 液体反应者定义为扩容后心指数(CI)增加≥15%。
- 去甲肾上腺素反应者定义为平均动脉压(MAP)增加≥15%。
- CRT最小显著变化为23%,变化大于23%视为显著。
- 基线CRT以3 s为界分组(<3 s或≥3 s)。
处置流程与药物剂量
- 扩容方案:500 mL生理盐水静脉输注。
- 去甲肾上腺素采用剂量增加方案(原文未写明具体剂量与目标值)。
- CRT测量:视频法,标准化指尖压力,连续测量5次。
研究设计与关键结果
- 研究类型:前瞻性干预研究(临床试验注册号NCT04870892),69例脓毒性休克患者。
- 基线CRT<3 s者(n=7)扩容后CRT平均不变。
- 基线CRT≥3 s且扩容后CI增加<15%的液体无反应者(n=13)中,除1例外CRT不变。
- 基线CRT≥3 s的液体反应者(n=13)中,8例CRT下降,其余不变,呈现CI与CRT反应分离。
- 存在CI与CRT分离的患者中,开始去甲肾上腺素>24 h后纳入的比例高于其他患者(60% vs. 0%)。
- 基线CRT≥3 s且去甲肾上腺素后MAP增加<15%者(n=6)中,除1例外CRT无显著变化。
- 基线CRT延长的去甲肾上腺素反应者(n=11)中,4例CRT升高,其余不变,呈现MAP与CRT反应分离。
证据类型、等级与局限
- 证据类型:前瞻性干预研究(临床试验注册号NCT04870892),伦理委员会批准号CE SRLF 21-25。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,CRT延长的脓毒性休克患者,当扩容增加心输出量<15%或增加去甲肾上腺素剂量使MAP增加<15%时,CRT极少改善。
- 作者认为,当液体对心输出量、去甲肾上腺素对MAP的影响显著时,CRT反应多变,部分患者下降、部分稳定,呈现大循环指标与CRT变化的分离;CRT表现如微循环标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Capillary refill time (CRT) has been suggested as a variable to follow during the course of septic shock. We systematically investigated the effects on CRT of volume expansion and norepinephrine.
METHODS: In 69 septic shock patients, we recorded mean arterial pressure (MAP), cardiac index (CI), and 5 consecutive CRT measurements (video method, standardized pressure applied on the fingertip) before and after a 500-mL saline infusion in 33 patients and before and after an increase of the norepinephrine dose in 36 different patients. Fluid responders were defined by an increase in CI ≥ 15%, and norepinephrine responders by an increase in MAP ≥ 15%.
RESULTS: The least significant change of CRT was 23%, so that changes in CRT were considered significant if larger than 23%. With volume expansion, CRT remained unchanged on average in patients with baseline CRT < 3 s (n = 7) and in all but one patient with baseline CRT ≥ 3 s in whom fluid increased CI < 15% (n = 13 "fluid non-responders"). In fluid responders with baseline CRT ≥ 3 s (n = 13), CRT decreased in 8 patients and remained unchanged in the others, exhibiting a dissociation between CI and CRT responses. The proportion of patients included > 24 h after starting norepinephrine was higher in patients with such a dissociation than in the other ones (60% vs. 0%, respectively). Norepinephrine did not change CRT significantly (except in one patient) if baseline CRT was ≥ 3 s and the increase in MAP < 15% (n = 6). In norepinephrine responders with prolonged baseline CRT (n = 11), it increased in 4 patients and remained unchanged in the other ones, which exhibited a dissociation between MAP and CRT responses.
CONCLUSIONS: In septic shock patients with prolonged CRT, CRT very rarely improves with treatment when volume expansion increases cardiac output < 15% and increasing norepinephrine increases MAP < 15%. When the effects of fluid infusion on cardiac output and of norepinephrine on MAP are significant, the response of CRT is variable, as it decreases in some patients and remains stable in others which exhibit a dissociation between changes in macrohemodynamic variables and in CRT. In this regard, CRT behaves as a marker of microcirculation.
TRIAL REGISTRATION: ClinicalTrial.gov (NCT04870892). Registered January15, 2021. Ethics committee approval CE SRLF 21-25.
参考来源
- Fage N, Moretto F, Rosalba D, et al. Effect on capillary refill time of volume expansion and increase of the norepinephrine dose in patients with septic shock. Crit Care. 2023. PMID: 37932812. doi:10.1186/s13054-023-04714-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。